CD34 and breast cancer: In multivariable analyses, donor age >36 years (HR 1.62 95% CI 1.07–2.44; p = 0.02), BC at HSCT (HR 1.76 95% CI 1.11–2.80; p = 0.02) and lower CD34+ dose (HR 1.12 95% CI 1.05–1.20; p = 0.001) for continous and for categorical (HR 1.67 95% CI 1.06–2.66) were independently associated with shorter PFS (Table 4).